Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings Inc (PETV) is a pioneering developer of biomedical devices for veterinary care, specializing in innovative solutions for animal joint health. This dedicated news hub provides investors and industry professionals with timely access to all official company announcements and press releases.
Track PetVivo's latest developments including product innovations like Spryng™ with OsteoCushion™ Technology, financial performance updates, and strategic partnerships. Our curated collection ensures stakeholders stay informed about regulatory milestones, clinical advancements, and market expansions in the pet therapeutics sector.
This resource serves as a centralized repository for critical updates affecting investment decisions and industry analysis. Users gain efficient access to verified information on licensing agreements, manufacturing developments, and subsidiary activities across PetVivo's operational network.
Bookmark this page for streamlined monitoring of PetVivo's progress in transforming veterinary medicine through adapted human medical technologies. Regularly updated to reflect the company's evolving position in the biomedical devices landscape.
PetVivo Holdings, a biomedical device company focused on innovative therapeutics for pets, will present at the Aegis Capital Virtual Conference from May 2nd to 4th, 2023. CEO John Lai will discuss the company's Spryng product featuring OsteoCushion Technology, aimed at managing lameness and joint issues in companion animals.
Spryng is an injectable device that supports joint health by mimicking natural cartilage and is currently available for sale. The presentation is scheduled for May 3rd, 2023, from 12:25 PM to 12:55 PM ET. PetVivo holds a strong patent portfolio, with 17 products in development and a unique market strategy focused on veterinary devices.
PetVivo Holdings (NASDAQ: PETV, PETVW) has appointed Mary Grace Rutland as the new Business Development Manager for the Mid-Atlantic Region. Rutland, with 24 years of experience in animal health sales, will focus on promoting Spryng with OsteoCushion technology to veterinarians across the U.S. CEO John Lai expressed excitement about her addition, highlighting her previous roles in the industry, including positions at Fort Dodge Animal Health and Neogen Corporation. PetVivo specializes in innovative medical devices for companion animals, with Spryng aimed at treating lameness and joint-related conditions like osteoarthritis in dogs and horses. The company has a pipeline of 17 products and holds 19 patents covering its biomaterials and methods.
FAQ
What is the current stock price of Petvivo Hldgs (PETV)?
What is the market cap of Petvivo Hldgs (PETV)?
